Journal Guide

Drug and Chemical Toxicology publishes full-length research papers, review articles and short communications that encompass a broad spectrum of toxicological data surrounding risk assessment and harmful exposure. Manuscripts are considered according to their relevance to the journal.

For nearly 50 years, DTB has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB was started in 1962. From the outset, it has provided healthcare professionals with independent, clear, reliable information and advice to help ensure patients get the best care. DTB conclusions represent a synthesis of the best available medical evidence with opinions from a wide range of commentators. Published monthly by BMJ, DTB is wholly independent of industry, Government and regulatory authorities and does not carry any display advertising or accept any form of commercial sponsorship.DTB provides articles based on a synthesis of evidence with opinions from a wide range of specialist and generalist commentators, typically over 40 individuals and organisations for each article. Over the years, DTB has initiated successful campaigns for the removal or restriction of medicines that it could not recommend, prompted withdrawal of excessive promotional claims and exposed fundamental weaknesses in certain prescribing practice.Surveys of our readership have consistently shown that readers find DTB authoritative and influential in relation to their decisions, recommendations or advice on treatments. These are just a few of the examples of why DTB is regarded as an indispensable part of evidence-based clinical practice and has been described as both essential reading for practising doctors and as a key information source by the House of Commons Health Select Committee in the UK.

Drugs in R&D is an international, peer reviewed, open access, online only journal, which provides timely information on emerging drug classes and new treatments for specific disorders in an ‘open access’ format for all to review. Original research and reviews from all phases of clinical development are included, with a strong link to clinical practice. Healthcare decision makers are thus provided with clinically applicable knowledge about the likely place in therapy of a drug.Journal issues comprise:·        Original research on new drugs, including clinical trials:·        New research on established drugs.·        R&D Insight reports:Short communications and letters to the editor are welcomed and will be considered for publication. Reviews may also be considered. All manuscripts are subject to peer review by international experts.

The journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.

Environmental Toxicology and Pharmacology publishes the results of studies concerning toxic and pharmacological effects of (human and veterinary) drugs and of environmental contaminants in animals and man.Areas of special interest are: molecular mechanisms of toxicity, biotransformation and toxicokinetics (including toxicokinetic modelling), molecular, biochemical and physiological mechanisms explaining differences in sensitivity between species and individuals, the characterisation of pathophysiological models and mechanisms involved in the development of effects and the identification of biological markers that can be used to study exposure and effects in man and animals.In addition to full length papers, short communications, full-length reviews and mini-reviews, Environmental Toxicology and Pharmacology will publish in depth assessments of special problem areas. The latter publications may exceed the length of a full length paper three to fourfold. A basic requirement is that the assessments are made under the auspices of international groups of leading experts in the fields concerned. The information examined may either consist of data that were already published, or of new data that were obtained within the framework of collaborative research programmes. Provision is also made for the acceptance of minireviews on (classes of) compounds, toxicities or mechanisms, debating recent advances in rapidly developing fields that fall within the scope of the journal.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

The European Journal of Clinical Pharmacology publishes original papers, short communications, and letters to the editors on all aspects of clinical pharmacology and drug therapy in humans. Coverage includes therapeutic trials; pharmacokinetics; drug metabolism; adverse drug reactions; drug interactions; all aspects of drug development; prescribing policies; pharmacoepidemiology; and matters relating to the safe use of drugs. Data from animal experiments are published only in the context of parallel experiments in man reported in the same paper. The journal also publishes review articles on special problems related to these areas, and encourages debate on controversial issues.

The European Journal of Drug Metabolism and Pharmacokinetics addresses all aspects of pre-clinical and clinical pharmacokinetics, including drug disposition, drug metabolism, drug transport, drug interactions, bioavailability and biopharmacy. The journal welcomes publications in the field of pharmacokinetic modeling. Analytical methods validation and bioequivalence studies will not be considered for publication. The journal publishes original articles, short preliminary communications, review articles on special topics, and conference proceedings.The European Journal of Drug Metabolism and Pharmacokinetics publishes four issues a year.

The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry: organic synthesis; biological behavior; pharmacological activity; drug design; QSAR; molecular modeling; drug-receptor interactions; molecular aspects of drug metabolism; prodrug synthesis and drug targeting. It provides a medium for publication of original papers, laboratory notes, short or preliminary communications, and invited reviews.Book Proposals: Elsevier also publishes books in this area. If you have a suggestion for a book topic or would like to submit a book proposal, please contact us at: chemistry@elsevier.comBenefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of chemicals in biological systems.The scope includes:Behavioural pharmacologyNeuropharmacology and analgesiaCardiovascular pharmacologyPulmonary, gastrointestinal and urogenital pharmacologyEndocrine pharmacologyImmunopharmacology and inflammationMolecular and cellular pharmacologyThe journal publishes full-length papers, short reviews (not exceeding 12 pages) and perspectives (by invitation only), intended to debate recent advances in rapidly developing fields.The table of contents for this journal is now available pre-publication, via e-mail, as part of the free ContentsDirect service from Elsevier. Please send an e-mail message to cdhelp@elsevier.co.uk for further information about this service.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

European Neuropsychopharmacology provides a medium for the prompt publication of articles in the field of neuropsychopharmacology. Its scope encompasses clinical and basic research relevant to the effects of centrally acting agents in its broadest sense.European Neuropsychopharmacology is the official journal of the European College of NeuropsychopharmacologyElectronic usage:An increasing number of readers access the journal online via ScienceDirect, one of the world's most advanced web delivery systems for scientific, technical and medical information.Average monthly article downloads for this journal: 24,961** Figure is a monthly average of full-text articles downloaded from ScienceDirect between July 2012 and July 2013

Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology and drug abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, brain imaging, genetics, neuroendocrinology, neuroscience, and pharmacology.One goal of the journal is to encourage increased attention to biologic factors that may influence both the pharmacodynamic and the pharmacokinetic effects of drugs. Recent research has shown the importance of examining the effects of sex and menstrual/estrous cycle phase on the effects of abused drugs, as well as responses to medications for the treatment of drug abuse and the alleviation of pain.The journal publishes original reports on the development and evaluation of new pharmacotherapies, the influence of genetics and hormones on responses to abused drugs and treatment medications, the pharmacological management of pain, and brain imaging studies of the neural correlates of drug effects.The journal will focus on clinical laboratory studies and controlled clinical medication trials as well as basic preclinical experiments on psychopharmacology and drug abuse.The journal also will include comprehensive and integrative reviews of advances in research on psychopharmacology. These reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches.Each year, the journal will recognize young investigators who are recipients of the Young Psychopharmacologist Award or the Best Dissertation Award, as well as midcareer and senior scientists who receive the Brady–Schuster Award from APA Division 28, Psychopharmacology and Substance Abuse. Awardees will be invited to submit a review paper based on their award-winning research.The journal may occasionally publish innovations in psychopharmacology that report a novel method, measure, or result. Commentary on the nature and implications of the innovation may be invited.The overall goal is to provide a forum for innovative clinical and preclinical research that advances our understanding of the behavioral and biological determinants of the effects of drugs.

Expert Opinion on Biological Therapy ranks #42 of 160 in the Biotechnology & Applied Microbiology category and #30 of 106 in the Medicine, Research & Experimental category in the 2009 ISI Journal Citation Reports.Expert Opinion on Biological Therapy (ISSN 1471-2598 [print], 1744-7682 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on all aspects of biological therapy, providing expert opinion on the scope for future development.The Editors welcome: * Reviews covering gene therapy and gene transfer technologies; therapeutic peptides and proteins; vaccines and antibodies; cell- and tissue-based therapies * Drug Evaluations reviewing the clinical data on a particular biological agent * Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practiceThe audience consists of scientists and managers in the healthcare and biopharmaceutical industry and others closely involved in the development of biological therapy for the treatment of human disease.

Expert Opinion on Drug Metabolism & Toxicology ranks #66 of 249 in the Pharmacology & Pharmacy category and #112 of 286 in the Biochemistry and Molecular Biology category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data * Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drugThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.

Expert Opinion on Emerging Drugs ranks #69 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.Each review article is structured to include: * Concise background to the subject matter * Assessment of medical need for alternative or novel therapies * Assessment of the market and anticipated changes over time * Summary of current research goals * Outline of the scientific rationale for the approach(es) considered< * Analysis of the competitive environment * Discussion of potential development issues * The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseasesThe audience consists of pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners.